Atlantic Edge Private Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
MCI
GA
BS
Atlantic Edge Private Wealth Management's REGN Position: Q2 2026 in Review
Atlantic Edge Private Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 1.7% in Q2 2026, selling an estimated $17K and leaving 1,449 shares worth $904K. The position accounts for 0.18% of the portfolio, ranked #83.
Atlantic Edge Private Wealth Management first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.77M in Q3 2024. 416 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Atlantic Edge Private Wealth Management held 1,449 shares of Regeneron Pharmaceuticals worth $904K as of Q2 2026.
- Atlantic Edge Private Wealth Management sold 25 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $17K.
- Regeneron Pharmaceuticals made up 0.18% of Atlantic Edge Private Wealth Management's portfolio in Q2 2026, its #83 holding.
- Atlantic Edge Private Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
- Atlantic Edge Private Wealth Management's Regeneron Pharmaceuticals position peaked at $1.77M in Q3 2024.
- 416 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Atlantic Edge Private Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.